
INCUBATE
@incub8coalition
Followers
258
Following
177
Media
251
Statuses
1K
We foster innovation, safeguard advancements, and amplify the results of life sciences investment.
Joined February 2019
@johnbstanford joined a breakout session at @BIOConvention on how to align policies impacting drug development with unmet patient need, where he discussed how policy can support innovation in areas like cancer and rare diseases.
0
0
0
RT @AUTM: Venture Partners at CU Boulder is awarding up to $50,000 to early-stage therapeutic projects, helping researchers bridge the fund….
colorado.edu
Venture Partners at CU Boulder has announced the first recipients of a new translational funding program designed to advance promising, early-stage therapeutics
0
1
0
In @Forbes, @sallypipes cites Incubate's Life Sciences Investment Tracker in her column on how IRA price-setting chills investment in drug research and development.
forbes.com
Buried within the One Big Beautiful Bill Act is a provision that could improve or even save the lives of the 30 million Americans suffering from rare diseases.
0
0
0
In the latest episode of @MakingMedPod, @johnbstanford welcomes @nyahphengsitthy of @BLaw to discuss the latest shifts in drug pricing, FDA policy, and the unpredictable pace of the Trump administration. See the full episode on the @MakingMedPod YouTube.
0
0
3
RT @FierceBiotech: Since 2022, China biotechs have developed 639 first-in-class drug candidates, a staggering 360% increase from 137 candid….
fiercebiotech.com
International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and patent expirations continue to rise. | International companies are...
0
4
0
In the latest edition of @MakingMedPod, @johnbstanford explains why the Trump administration is considering tariffs on imported medicines and what it means for the life sciences industry and American patients.
0
0
0
A Leerink analysis shows prices for top-selling drugs fall 87-99% due to generic competition. In the DOJ and FTC's next listening session, government officials should explore how PBMs block access to these low-cost options.
leerink.com
Leerink Partners' Articles – sharing our deep expertise and experience in Healthcare to help fuel our customers' next breakthrough innovation.
0
0
0
RT @BSBHbyVT: The Inflation Reduction Act's (IRA) pill penalty is reshaping oncology pipelines, as early-stage funding for high-Medicare-ex….
0
1
0
In an interview with @statnews, @JFruehauf of Mission BioCapital, LabCentral, and BioLabs, warns that "we in the U.S. are questioning our desire to lead" in biotech -- a sector that the U.S. has led since the '70s.
statnews.com
A well-placed biotech investor says U.S. policies are straining life sciences startups — and more disruption is coming.
0
0
1
In this week's @MakingMedPod, Incubate's executive director, @johnbstanford discusses how President Trump views tariffs as leverage for negotiations with other nations more than the end goal, and why that mindset matters as a possible 200% tariff on pharmaceuticals looms ahead.
0
0
0
In the new episode of @MakingMedPod, @johnbstanford covers Trump's escalating tariffs -- what they mean for global trade, why medicines are in the crosshairs, and how they could increase the cost of drugs. See the full episode on the @MakingMedPod YouTube.
0
0
1
In his @PharmExec Q&A interview, @johnbstanford warns that proposals like Most Favored Nation drug pricing could disrupt the investment pipeline that fuels medical breakthroughs.
pharmexec.com
New rules places upon the pharma industry will have a significant impact on how investors view the industry.
0
0
0
New @LeerinkPartners research shows that prices for most top-selling drugs drop as much as 98% after about 13 years on the market. Fixing Medicare's pill penalty, as the EPIC Act proposes, would protect the market forces that drive life science innovation.
0
0
0
As regulatory uncertainty grows, early-stage biotech startups are concerned about dwindling investment and confidence in the sector. Read more about Incubate's survey of CEOs in @qz:
0
0
0
In the latest episode of @MakingMedPod, @johnbstanford unpacks what didn't make it into the One Big Beautiful Bill Act. He highlights the good, like the exclusion of a Most Favored Nation policy, and the disappointing, including the absence of the EPIC Act pill penalty fix.
0
0
0
In the newest episode of @MakingMedPod, @johnbstanford discusses why the One Big Beautiful Bill Act is a pro-business bill and what notable inclusions like the ORPHAN Cures Act mean for the biotech community. Watch the full episode on YouTube:.
0
0
0
A new episode of @MakingMedPod is here! In this episode, @johnbstanford breaks down what made it into the One Big Beautiful Bill Act - like the ORPHAN Cures Act -- and what didn't, including the EPIC Act and PBM reforms. See the full episode on the @MakingMedPod Youtube.
0
0
1